ImmuCell Corporation (ICCC) P/E Ratio History
Deep ValueTrading at -82.6x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 1995–2025
Loading P/E history...
P/E Ratio Analysis
As of June 30, 2026, ImmuCell Corporation (ICCC) trades at a price-to-earnings ratio of -82.6x, with a stock price of $9.91 and trailing twelve-month earnings per share of $-0.06.
The current P/E is 163% below its 5-year average of 131.0x. Over the past five years, ICCC's P/E has ranged from a low of 17.9x to a high of 1051.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, ICCC trades at a 461% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.6x.
Relative to the broader market, ICCC trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ICCC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ICCC Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ICCC P/E vs Peers
Vaccines and Infectious Disease peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $987M | 156.8 | - | +107% | |
| $1B | 26.7 | 3.58 | +1883%Best | |
| $13M | 7.5 | - | -15% | |
| $31B | 12.2 | 1.02Best | +10% | |
| $43B | 41.0 | 2.87 | +23% | |
| $2B | 3.7Lowest | - | +307% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ICCC Historical P/E Data (1995–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | - | $6.25 | $0.26 | 24.2x | -69% |
| FY2025 Q2 | Jun 30 2025 | $6.96 | $0.19 | 37.2x | -52% |
| FY2022 Q2 | - | $8.69 | $0.04 | 242.7x | +213% |
| FY2022 Q1 | - | $9.65 | $0.14 | 67.0x | -14% |
| FY2021 Q3 | - | $9.36 | $0.01 | 1051.7x | +1258% |
| FY2017 Q3 | Sep 30 2017 | $6.50 | $0.01 | 492.4x | +536% |
| FY2017 Q2 | Jun 30 2017 | $7.33 | $0.09 | 80.4x | +4% |
| FY2017 Q1 | Mar 31 2017 | $5.53 | $0.13 | 41.3x | -47% |
| FY2016 Q4 | Dec 31 2016 | $5.95 | $0.12 | 48.0x | -38% |
| FY2016 Q3 | Sep 30 2016 | $7.73 | $0.19 | 40.0x | -48% |
| FY2016 Q2 | - | $6.90 | $0.29 | 23.5x | -70% |
| FY2016 Q1 | - | $6.85 | $0.33 | 21.1x | -73% |
| FY2015 Q4 | - | $7.54 | $0.37 | 20.6x | -73% |
| FY2015 Q3 | Sep 30 2015 | $5.95 | $0.33 | 17.9x | -77% |
| FY2015 Q2 | - | $7.85 | $0.23 | 34.7x | -55% |
| FY2015 Q1 | - | $6.29 | $0.10 | 63.5x | -18% |
| FY2013 Q4 | - | $4.27 | $0.04 | 100.9x | +30% |
| FY2013 Q3 | Sep 30 2013 | $4.73 | $0.09 | 54.7x | -29% |
| FY2013 Q2 | Jun 30 2013 | $3.76 | $0.05 | 82.8x | +7% |
| FY2013 Q1 | Mar 31 2013 | $3.68 | $0.05 | 76.3x | -1% |
| FY2012 Q4 | Dec 31 2012 | $4.00 | $0.03 | 141.8x | +83% |
| FY2012 Q3 | Sep 30 2012 | $5.11 | $0.03 | 152.1x | +96% |
| FY2012 Q2 | Jun 30 2012 | $5.85 | $0.01 | 491.6x | +535% |
| FY2008 Q2 | Jun 30 2008 | $3.47 | $0.09 | 37.5x | -52% |
| FY2008 Q1 | Mar 31 2008 | $3.44 | $0.15 | 22.3x | -71% |
| FY2007 Q4 | Dec 31 2007 | $3.55 | $0.22 | 15.8x | -80% |
| FY2007 Q3 | Sep 30 2007 | $4.30 | $0.25 | 17.0x | -78% |
| FY2007 Q2 | Jun 30 2007 | $5.99 | $0.19 | 31.1x | -60% |
| FY2007 Q1 | Mar 31 2007 | $5.43 | $0.22 | 24.3x | -69% |
| FY2006 Q4 | Dec 31 2006 | $5.95 | $0.22 | 26.6x | -66% |
| FY2006 Q3 | Sep 30 2006 | $4.93 | $0.26 | 18.9x | -76% |
| FY2006 Q2 | Jun 30 2006 | $4.98 | $0.24 | 20.7x | -73% |
| FY2006 Q1 | Mar 31 2006 | $6.77 | $0.26 | 25.9x | -67% |
| FY2005 Q4 | Dec 31 2005 | $5.25 | $0.25 | 20.9x | -73% |
| FY2005 Q3 | Sep 30 2005 | $5.01 | $0.17 | 29.1x | -62% |
| FY2005 Q2 | - | $4.52 | $0.13 | 34.6x | -55% |
| FY2005 Q1 | - | $4.26 | $0.08 | 53.6x | -31% |
| FY2004 Q4 | Dec 31 2004 | $7.16 | $0.05 | 144.6x | +87% |
| FY2003 Q4 | Dec 31 2003 | $3.87 | $0.14 | 26.9x | -65% |
| FY2003 Q3 | - | $2.74 | $0.45 | 6.1x | -92% |
| FY2003 Q2 | Jun 30 2003 | $2.53 | $0.47 | 5.3x | -93% |
| FY2003 Q1 | Mar 31 2003 | $1.94 | $0.51 | 3.8x | -95% |
| FY2002 Q4 | - | $1.68 | $0.32 | 5.2x | -93% |
| FY2002 Q3 | Sep 30 2002 | $1.80 | $0.15 | 11.6x | -85% |
| FY2002 Q2 | Jun 30 2002 | $2.71 | $0.12 | 21.8x | -72% |
| FY2002 Q1 | Mar 31 2002 | $3.15 | $0.17 | 18.3x | -76% |
| FY2001 Q4 | Dec 31 2001 | $3.65 | $0.15 | 23.9x | -69% |
| FY2001 Q3 | Sep 30 2001 | $2.95 | $0.78 | 3.8x | -95% |
| FY2001 Q2 | Jun 30 2001 | $2.60 | $0.79 | 3.3x | -96% |
| FY2001 Q1 | Mar 31 2001 | $2.50 | $0.77 | 3.2x | -96% |
| FY2000 Q4 | Dec 31 2000 | $1.56 | $0.81 | 1.9x | -98% |
| FY2000 Q3 | Sep 30 2000 | $2.38 | $0.15 | 15.4x | -80% |
| FY2000 Q2 | Jun 30 2000 | $3.69 | $0.18 | 20.6x | -73% |
| FY2000 Q1 | Mar 31 2000 | $4.50 | $0.19 | 23.8x | -69% |
| FY1999 Q4 | Dec 31 1999 | $2.38 | $0.21 | 11.3x | -85% |
| FY1999 Q3 | - | $1.94 | $0.15 | 12.9x | -83% |
| FY1999 Q2 | Jun 30 1999 | $1.38 | $0.09 | 16.2x | -79% |
| FY1999 Q1 | Mar 31 1999 | $1.16 | $0.01 | 77.1x | -0% |
| FY1998 Q3 | Sep 30 1998 | $1.94 | $0.17 | 11.1x | -86% |
| FY1998 Q2 | - | $2.19 | $0.22 | 9.9x | -87% |
| FY1998 Q1 | - | $1.94 | $0.17 | 11.4x | -85% |
| FY1997 Q4 | Dec 31 1997 | $2.47 | $0.15 | 16.5x | -79% |
| FY1997 Q3 | - | $2.56 | $0.06 | 46.0x | -41% |
| FY1997 Q2 | Jun 30 1997 | $2.75 | $0.01 | 482.5x | +523% |
| FY1997 Q1 | Mar 31 1997 | $2.25 | $0.04 | 63.0x | -19% |
| FY1995 Q4 | Dec 31 1995 | $2.44 | $0.01 | 243.8x | +215% |
| FY1995 Q1 | Mar 31 1995 | $1.25 | $0.02 | 62.5x | -19% |
Average P/E for displayed period: 77.4x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
31+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ICCC — Frequently Asked Questions
Quick answers to the most common questions about buying ICCC stock.
What is ICCC's P/E ratio?
ImmuCell Corporation (ICCC) trailing twelve-month P/E ratio is -82.6x, based on TTM diluted EPS of $-0.06. The 5-year average P/E is 131.0x and the historical range spans 17.9x to 1051.7x.
Is ICCC stock overvalued or undervalued?
ICCC trades at -82.6x P/E, below its 5-year average of 131.0x. At the 0th percentile of its historical range (17.9x–1051.7x), the stock is priced at a discount to its own history.
Is ICCC stock expensive?
No, ICCC is not expensive on a historical basis. The current P/E of -82.6x is below the 5-year average of 131.0x and sits at the 0th percentile of its valuation range.
What is ICCC's historical P/E range?
Over the past 5 years, ICCC's P/E ratio has ranged from 17.9x to 1051.7x, with a median of 54.7x and an average of 131.0x. The current P/E of -82.6x places the stock at the 0th percentile of this range. Full historical data spans 1995–2025.
How does ICCC's P/E compare to the S&P 500?
ICCC trades at -82.6x P/E versus the S&P 500 median of 25.1x. The 429% discount to the market suggests lower growth expectations or perceived higher risk.
How does ICCC's valuation compare to Healthcare peers?
ImmuCell Corporation P/E of -82.6x compares to the Healthcare sector median of 22.9x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ICCC's PEG ratio?
ICCC PEG ratio is N/A, based on a P/E of -82.6x and EPS growth of 53.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ICCC's earnings yield?
ICCC earnings yield is N/A, the inverse of its -82.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.